Aging cells link lung disease and metabolic decline
Chronic lung diseases and metabolic conditions like type 2 diabetes seem unrelated. But aging cells that accumulate in lungs and fatty tissue may be driving both.
As people grow older, damaged cells build up in tissues throughout the body. These so-called senescent cells stop dividing but do not die. Instead, they secrete a cocktail of inflammatory and pro-fibrotic signals that harm surrounding tissue. The researchers describe how this mechanism may serve as a common biological link between chronic pulmonary diseases and metabolic disorders such as obesity and type 2 diabetes.
Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis both rise sharply with age. So do obesity and type 2 diabetes. These conditions also co-occur more frequently than chance would predict. The hypothesis is that senescent cells play a central role in both: through persistent inflammation and signals that promote scarring (fibrosis), they sustain a self-reinforcing cycle of tissue damage.
Clearing out aging cells
Therapies that selectively eliminate senescent cells are known as senolytics. In animal models, they show promising results against pulmonary fibrosis. A small human trial in patients with idiopathic pulmonary fibrosis also produced encouraging signals, but little follow-up has occurred. The reason is largely economic: cheap or generic drugs cannot easily attract the funding needed for large clinical trials.
Beyond dedicated senolytics, the authors also highlight existing medications used for type 2 diabetes that appear to reduce senescent cell accumulation as a secondary effect. Whether this contributes to their organ-protective properties remains to be established.
A shared biological denominator
The broader implication is that cellular senescence may be a shared biological denominator for diseases we typically treat in isolation. People aging with both obesity and lung problems may carry a higher burden of senescent cells across multiple tissues simultaneously. Targeting that underlying mechanism could, in theory, address several conditions at once. But the clinical evidence is still limited, and the authors are clear about what remains unknown.
Want to research this yourself?
Search for example:
- cellular senescence pulmonary fibrosis
- senolytic therapy chronic lung disease
- inflammaging metabolic disease